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EDITORIALS

Plasma Matrix Metalloproteinase-9 and Diabetic
Microalbuminuria: Tip of the Iceberg?
Related Article, p. 544

HE REPORT by Ebihara et al1 currently
establishes an elevated plasma level of matrix metalloproteinase-9 (MMP-9) as the earliest
marker of diabetic renal disease. The authors
prospectively followed 30 non–insulin-dependent diabetic subjects for 48 months while monitoring plasma levels of MMP-9, MMP-1, tissue
inhibitor of metalloproteinase-1 (TIMP-1), and
microalbuminuria, the well-established benchmark of early diabetic glomerulopathy and possibly other renal disorders. Their careful studies of
eight patients who developed microalbuminuria
demonstrated that plasma elevations of MMP-9
preceded the onset of microalbuminuria in all
eight patients by at least 3 years. Intriguingly, in
the microalbuminuric subset, conventional
therapy with an angiotensin-converting enzyme
(ACE) inhibitor for 6 months abolished the increments of MMP-9 and decreased, in parallel, the
microalbuminuria. However, significant alterations of the plasma levels of MMP-1 and its
principal inhibitor, TIMP, did not occur.
The matrix MMPs constitute a 15-member
family of metalloendopeptidases engaged in the
physiologic and pathologic turnover of the matrix proper and cell surface proteins.2 These
zinc-dependent, latently secreted enzymes remodel the extracellular matrix in the pericellular
environment in conjunction with tissue serine
proteinases (eg, thrombin, tissue plasminogen
activator, urokinase, and plasmin), adamalysins,
and bone morphogenetic proteins. Acting in concert, the MMPs have the capability to degrade all
components of the extracellular matrix. MMPs
are inhibited by TIMP-1 and TIMP-2. MMPs
and TIMPs are regulated primarily at the transcriptional level either coordinately or reciprocally by a host of factors, including tumor promoters, retinoids, glucocorticoid steroids, cytokines,
and the matrix itself.3 Disruption of the balance

T

r 1998 by the National Kidney Foundation, Inc.
0272-6386/98/3204-0022$3.00/0

between MMPs and TIMPs leads to either net
matrix degradation or accrual. Normal functions
of MMPs and TIMPs include regulation of cell
migration, involution and apoptosis of the lactating mammary gland, morphogenesis in organismic development, and wound healing. Overzealous matrix degradation following overexpression
of MMPs has been correlated with tumor metastasis, synovial degradation of rheumatoid pannus, and sinusoidal disintegration in the inflamed
cirrhotic liver. Abrogation of such events by
countervailing overexpression of TIMP in animal models has established the role of MMPs in
these phenomena. Moreover, unrestrained overexpression of TIMPs has been documented in
fibrogenic disorders. For example, exuberant expression of TIMP-1 by dermal fibroblasts occurs
in progressive systemic sclerosis.4 In the kidney,
a defined role of MMPs and TIMPs in the pathogenesis of diabetic renal dysfunction is less clear.
MMPs and TIMPs are produced by a variety
of cells housed within both glomerular and tubular compartments.5 Diabetic glomerulosclerosis,
readily verifiable at the time of kidney biopsy, is
histologically evident as a primarily fibrotic lesion. Indeed, prognostic correlation is revealed
by the degree of tubulointerstitial fibrosis. How
then, could accelerated MMP-mediated proteolysis lead to a fibrogenic response? Following the
paradigm of experimental hepatic inflammation
invoked by carbon tetrachloride that eventuates
in fibrotic cirrhosis, we can at least envision such
a scenario.6 In this model, there is first proteolytic destruction of the sinusoidal architecture.
Healing by secondary intention, with scarring,
follows repression or recession of MMP-3 activity and/or dominance of TIMP-mediated inhibitory capacity. Thus, acute perturbations of the
normally balanced synthesis and degradation of
matrix resulting from equivalent MMP and TIMP
activities may result in loss of the scaffolding of
an organ’s cellular mass and its consequent replacement by scar tissue. Such a spatiotemporal
evolution is mirrored in diabetic glomerulosclerosis in which mesangial cell expansion precedes, by years, the development of glomerular
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and interstitial fibrosis. That this thematic requires one or two decades to be completely
manifest has forestalled our appreciation of it. A
principal operative in this drama may be the
mesangial cell, a multipotent pericyte that can
secrete several MMPs and TIMP-1. The mesangial cell has been shown to participate in a
proteolytic cascade in vitro with serine proteases
such as plasmin, which can be activated at glomerular loci of inflammation.5-7 Juxtaposed
against endothelial cells within capillary loops,
the products induced from these cells are naturally focused against their targets. In addition,
the mesangial cell also becomes a target for
soluble mediators of inflammation and fibrosis
(eg, such as the chemokines, interleukin-1␤, tumor necrosis factor-␤, and transforming growth
factor-␤. Tumor necrosis factor-␣ has been shown
to upregulate monocytic recruitment into early
renal diabetic lesions while transforming growth
factor-␤ provides a local microenvironmental
fibrogenic stimulus for progressive glomerulosclerosis and which is also upregulated in the
hyperglycemic milieu.1 Nearly all of these factors influence net proteolytic activity via MMP/
TIMP interactions that may, in turn, be regulated
by changes in glomerular dynamics (ie, volume
and stretch) as implied in the data reported by
Cortes et al.8 However, none of these mediators
has been associated with an increased plasma
level in diabetic nephropathy.
MMP-9, the 92-kd gelatinase B, is expressed
by many cell types, including endothelial cells,
immune cells, and parenchymal cells. Enhanced
MMP-9 proteolytic activity by glomerular epithelial cells has been intimated as one mechanism
underlying the pathophysiology of glomerular
proteinuria that characterizes diabetic renal disease and other glomerular disorders.9 However,
renal tubular cells produce MMP-9. Proteolysis
from this MMP might conceivably be of tubular
origin rather than glomerular origin.6,10 Because
extensive glomerular-tubular or tubular-glomerular ‘‘cross-talk’’ might occur, this possibility is
quite tenable, especially considering that the
bulk of the kidney comprises cells within the
tubulointerstitium. In addition, interactions among
various MMPs and other proteases could lead to
a proteolytic cascade that ultimately results in
augmented MMP-9 activity. Activated MMP-3
can activate pro-MMP-9 and foster development
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of a wave of proteolysis.3,6 With its broad substrate specificity, this MMP, which includes proteoglycans, collagens, and fibronectin, is produced by several indigenous renal cells, including
tubular cells, mesangial cells, and cortical fibroblasts (unpublished observations). In fact, a recent report by Suzuki et al5 demonstrated increased glomerular MMP-3 expression in kidney
biopsy specimens from individuals afflicted with
immunoglobulin A nephropathy and diabetes mellitus. Plasma and MMP-3 levels were not measured in the study. Had only plasma or urinary
MMP-3 levels been elevated, however, these
findings would not unequivocally establish that
the source of the MMP-3 was of renal origin.
Multiple sources exist to produce and secrete
MMP-3. In addition, elevation of a urinary factor
such as transforming growth factor-␤ in a crescentic model of glomerulonephritis does not equate
to pathogenesis. It may, however, implicate a
particular cytokine or other mediator as central
to a renal disorder.11
The fact that MMP-9 is a product of the
endothelium enhances the hypothesis that the
vasculopathy of diabetes produces the findings
reported by Ebihara et al.1 However, there is no
proof of this extant, and an inflammatory lesion
involving the endothelium of glomerular capillary loops has not been described, as might be
expected in an aggressive and active lesion that
is overexpressing MMP-9. Perhaps, though, diabetic microalbuminuria represents ‘‘the tip of the
iceberg,’’ reflecting the glomerular endovascular
damage that precedes more widespread endothelial dysfunction elsewhere. The seminal data of
Stehouwer et al12 demonstrating elevated plasma
von Willebrand factor levels in diabetic microalbuminuria support this construct.
Ebihara et al1 treated microalbuminuric patients in conventional fashion with an ACE inhibitor, cilazapril. Although captopril has been shown
to downregulate renal MMP-2 and -9 activities,
possibly by interfering with the zinc-binding
coordination sites of these enzymes, the repression of plasma MMP-9 toward control levels by
the institution of ACE inhibition does not clarify
whether the elevations of MMP derive from the
kidney. This compound could be altering the
balance of proteolysis elsewhere, particularly in
the endothelium, which can remodel itself through
altering its regulation of MMP activity.13
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Despite the small number of patients and the
conundrum regarding the origin of elevated
plasma MMP-9 levels, the finding of Ebihara et
al1 (ie, that an almost indiscernible increment of
proteolytic activity in the diabetic kidney spawns
our earliest clinical manifestation of diabetic
renal disease, microalbuminuria) represents a
most fertile area for continued study. We await
future studies that will localize the presence of
MMP-9 in the diabetic human kidney, at the gene
and protein levels, and those that determine the
urinary levels of this powerful proteinase. If such
studies demonstrate a clear-cut role of MMP-9 in
the advent of diabetic nephropathy, then therapeutic targeted inhibition of this MMP, and possibly
others, may amplify the salutary effects of ACE
inhibition.
—Jerry Yee, MD
Division of Nephrology/Hypertension
Henry Ford Hospital
Detroit, MI
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